Shattuck Labs, Inc. Common Stock
$5.88
-$0.09 (-1.51%)
$5.78Day Range$6.12
Key Statistics
Market Cap
$599.17M
Shares Outstanding
100.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 9, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$6.00
Day High
$6.12
Day Low
$5.78
Volume
743.1K
VWAP
$5.94
Prev Close
$5.97
Transactions
--
Acc. Volume
--
About Shattuck Labs, Inc. Common Stock
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
PHARMACEUTICAL PREPARATIONSSIC 283440 employees500 W. 5TH STREET, AUSTIN, TX, 78701512-900-4690IPO Oct 9, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001680367
- Composite FIGI
- BBG00V776CQ7
- Share Class FIGI
- BBG00V776CR6
- Ticker Root
- STTK
- SIC Code
- 2834
About Shattuck Labs, Inc. Common Stock (STTK) Stock
Shattuck Labs, Inc. Common Stock (STTK) closed the 2026-09-16 session at $5.88, down 1.51% versus the previous close (-0.09). The stock opened at $6.00 and traded between $5.78 and $6.12 during that session. Session trading volume was 743K shares. The volume-weighted average price (VWAP) is $5.94.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Shattuck Labs, Inc. Common Stock has a market capitalization of $599.2 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. STTK is listed on the XNAS exchange. The company employs approximately 40 people. Shattuck Labs, Inc. Common Stock is headquartered in AUSTIN, TX. The recorded listing date is 2020-10-09.
On this page you can find market STTK stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.